List view / Grid view
24 September 2015 | By Victoria White
Disregulation of MALT1 is associated with some subsets of lymphoma suggesting that MALT1 could be a promising drug target for these types of cancer...
24 September 2015 | By Victoria White
Deubiquitylating enzymes (DUBs) are involved in multiple cellular processes, including DNA damage and cell proliferation, and the inhibition of these enzymes has considerable potential for the generation of novel drugs...
History has demonstrated that the use of companion in vitro diagnostic tests to select cancer patients positive for a drug target significantly improves response to targeted anti-cancer therapies...
22 September 2015 | By Victoria White
The companies are validating the druggability of two kinase targets in a specific genetic context and have generated multiple novel chemical series against these targets...
21 September 2015 | By Drug Target Review
Included in this issue: Drug Development, Microfluidics, Proteomics, Ion Channels, GPCR, Imaging, Flow Cytometry, Enzymes
21 September 2015 | By Victoria White
Dr Wood's expertise and experience to support Nuevolution in developing its pipeline in oncology, inflammation and immuno-oncology...
In our Imaging In-Depth Focus: Dimitri Scholz and Jeremy C. Simpson from University College Dublin discuss trends in contemporary microscopy, Rudi Marquez and Zuzana Flachbartova share the bright future for molecular probes and Grischa Chandy from Molecular Devices LLC discusses changes and advantages with HCS microscopy...
21 September 2015 | By Victoria White
Appreciating the importance of the US biotechnology and pharmaceutical market, Selvita decided to come closer to its partners and clients and open a fully-owned US subsidiary, Selvita Inc...
Microfluidic miniaturisation, or the so-called ‘lab-on-a-chip’ concept, now encroaches on the fields of biology, medicine and pharmacology, and the nature of microfluidic technology (small volumes and high-throughput integration of fluid connections) means that it is outperforming conventional bench work. There has been an incredible need for microfluidic technology in the…
21 September 2015 | By SomaLogic
The SOMAscan™ assay is a highly multiplexed, sensitive, quantitative and reproducible proteomic tool for discovering biomarkers for drug discovery...
21 September 2015 | By BioTek
The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications...
In much the same way that kinases and phosphatases attach and remove phosphate groups from proteins to modulate their activity, there are a series of enzymes (E1, E2, E3) that add one or more ubiquitins onto a protein, as well as enzymes that remove them (deubiquitinases; DUBs), thereby regulating their…
16 September 2015 | By Victoria White
A team at the International Centre for Genetic Engineering and Biotechnology (ICGEB) will join forces with MRC Technology to take on the project...
15 September 2015 | By
Since initiating the project in 2014, significant progress has been made towards the invention of new compounds with activity against both gram-positive and gram-negative bacteria...
14 September 2015 | By IntelliCyt
Immunology Screening on the iQue Screener: Assays for Immune-Modulators and Immunotherapy...
